- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic Therapy of Metastatic Melanoma: On the Road to Cure
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 6, Pages 1430
Publisher
MDPI AG
Online
2021-03-22
DOI
10.3390/cancers13061430
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma
- (2020) Justin C. Moser et al. ACTA ONCOLOGICA
- Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
- (2020) Frank Friedrich Gellrich et al. Journal of Clinical Medicine
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
- (2020) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Systemic Therapy for Melanoma: ASCO Guideline
- (2020) Rahul Seth et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
- (2020) Amod Sarnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
- (2020) Isabella Claudia Glitza et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.
- (2020) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.
- (2020) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
- (2020) Ines Pires Da Silva et al. JOURNAL OF CLINICAL ONCOLOGY
- The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.
- (2020) Elisa A. Rozeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
- (2020) Daniel Olson et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
- (2020) Helen Gogas et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.
- (2020) Francesca Corti et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Advanced Melanoma in 2020 and Beyond
- (2020) Russell W. Jenkins et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
- (2020) Adi Diab et al. Cancer Discovery
- Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
- (2020) Teresa Amaral et al. Journal for ImmunoTherapy of Cancer
- ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee
- (2020) U. Keilholz et al. ANNALS OF ONCOLOGY
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
- (2020) Pengfei Cui et al. Scientific Reports
- LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
- (2020) P. Nathan et al. ANNALS OF ONCOLOGY
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- (2019) Celeste Lebbé et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
- (2019) Y J L Jansen et al. ANNALS OF ONCOLOGY
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort
- (2019) Pauline Tétu et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
- (2019) Hussein Abdul-Hassan Tawbi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) Daniel G. Coit et al. Journal of the National Comprehensive Cancer Network
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
- (2019) Chune Yu et al. Frontiers in Immunology
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) O Michielin et al. ANNALS OF ONCOLOGY
- 1311OLong-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)
- (2019) G V Long et al. ANNALS OF ONCOLOGY
- LBA69Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial
- (2019) A M Arance et al. ANNALS OF ONCOLOGY
- The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review
- (2019) Mark P. Opijnen et al. INTERNATIONAL JOURNAL OF CANCER
- Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma
- (2019) Irene L. M. Reijers et al. Pigment Cell & Melanoma Research
- Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
- (2019) Hamid et al. Cancers
- Cutaneous melanoma: From pathogenesis to therapy (Review)
- (2018) Giulia Leonardi et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
- (2018) Lucia Demkova et al. Molecular Cancer
- FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
- (2018) A C Tan et al. ANNALS OF ONCOLOGY
- Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.
- (2018) Brigitte Dreno et al. JOURNAL OF CLINICAL ONCOLOGY
- Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.
- (2018) Takami Sato et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
- (2018) Marvin Kuske et al. PHARMACOLOGICAL RESEARCH
- HGF/c-MET Signaling in Melanocytes and Melanoma
- (2018) Malgorzata Czyz INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
- (2018) Paolo A. Ascierto et al. JAMA Oncology
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
- (2017) Deborah Charych et al. PLoS One
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
- (2016) Praveen K. Bommareddy et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
- (2016) Matteo S Carlino et al. BRITISH JOURNAL OF CANCER
- Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial:
- (2016) F. Stephen Hodi et al. CANCER RESEARCH
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
- (2016) Robert H. I. Andtbacka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Complete remission of metastatic melanoma upon BRAF inhibitor treatment – what happens after discontinuation?
- (2015) Henrike Tolk et al. MELANOMA RESEARCH
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Melanoma
- (2015) Dirk Schadendorf et al. Nature Reviews Disease Primers
- MITF in melanoma: mechanisms behind its expression and activity
- (2014) Mariusz L. Hartman et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
- (2014) G. Chen et al. CLINICAL CANCER RESEARCH
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of the PI3K-AKT Pathway in Melanoma
- (2012) Michael A. Davies CANCER JOURNAL
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Monoclonal TCR-redirected tumor cell killing
- (2012) Nathaniel Liddy et al. NATURE MEDICINE
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic factors for survival in melanoma patients with brain metastases
- (2010) Michael A. Davies et al. CANCER
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current systemic therapy for metastatic melanoma
- (2009) Sanjiv S Agarwala Expert Review of Anticancer Therapy
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started